Vantage Financial Partners Ltd. Inc. Trims Holdings in Celgene Corporation (CELG)
Vantage Financial Partners Ltd. Inc. reduced its stake in Celgene Corporation (NASDAQ:CELG) by 75.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 949 shares of the biopharmaceutical company’s stock after selling 2,951 shares during the period. Celgene Corporation makes up 0.7% of Vantage Financial Partners Ltd. Inc.’s portfolio, making the stock its 24th largest holding. Vantage Financial Partners Ltd. Inc.’s holdings in Celgene Corporation were worth $949,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CELG. Oaktop Capital Management II L.P. bought a new stake in Celgene Corporation in the 2nd quarter valued at $271,605,000. Harbour Capital Advisors LLC increased its holdings in Celgene Corporation by 12,913.6% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 1,575,074 shares during the last quarter. Investec Asset Management LTD bought a new stake in Celgene Corporation in the 1st quarter valued at $194,490,000. Clearbridge Investments LLC increased its holdings in Celgene Corporation by 24.1% in the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the last quarter. Finally, State Street Corp increased its holdings in Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Institutional investors own 79.16% of the company’s stock.
CELG has been the subject of a number of recent research reports. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research note on Thursday, August 10th. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 27th. UBS AG cut shares of Celgene Corporation from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective for the company. in a research note on Thursday, October 26th. BMO Capital Markets dropped their price objective on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Finally, BTIG Research reissued a “neutral” rating on shares of Celgene Corporation in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $139.64.
In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Vantage Financial Partners Ltd. Inc. Trims Holdings in Celgene Corporation (CELG)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/16/vantage-financial-partners-ltd-inc-trims-holdings-in-celgene-corporation-celg.html.
Shares of Celgene Corporation (CELG) opened at $100.34 on Thursday. The stock has a market cap of $77,834.16, a PE ratio of 15.45, a price-to-earnings-growth ratio of 0.76 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.58 EPS. equities research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.